Printer Friendly

COMPUMED AND RHONE-POULENC RORER SIGN AGREEMENT TO PROMOTE BONE MINERAL DENSITY TESTS

 COLLEGEVILLE, Pa., Nov. 19 ~PRNewswire~ -- Rhone-Poulenc Rorer Pharmaceuticals (NYSE: RPR) has announced today that it has signed an agreement with CompuMed, Inc. (NASDAQ: CMPD), a computer-based medical equipment company, to provide free annual bone mineral density tests for approximately 40,000 patients with osteoporosis.
 RPR will promote CompuMed's OsteoGram(TM), a test that utilizes standard X-ray equipment to measure bone mineral density as an indicator of osteoporosis.
 A bone mineral density measurement can often be helpful in deciding whether to begin a program to prevent or treat postmenopausal osteoporosis, a disease which affects more than 25 million American women. Commonly known as the "silent thief," most women don't know they have osteoporosis until after a fracture has occurred.
 In an effort to help preserve bone mass, RPR and CompuMed will create awareness among physicians that bone mass testing can be conducted conveniently and for less expense in their office.
 RPR will promote OsteoGram(TM) from CompuMed for use in its ongoing Compliments of Calcimar(R) program(A). This will allow RPR to provide free annual bone mineral density tests to up to 40,000 patients enrolled in the program.
 Calcimar (calcitonin salmon) Injection, Synthetic is indicated for the treatment of postmenopausal osteoporosis in conjunction with adequate calcium and vitamin D to prevent the progressive loss of bone mass.
 RPR's specialized sales force will also distribute free OsteoGram(TM) starter kits to approximately 10,000 physicians who frequently treat patients with osteoporosis. In addition, RPR will discuss the OsteoGram(TM) at professional meetings and symposia to reach a broader physician population.
 RPR will negotiate for acquisition of international rights to promote OsteoGram(TM) on a country-by-country basis in those countries in which RPR has an interest.
 CompuMed also designs, manufactures and distributes its own line of computer-based cardiopulmonary medical equipment for use by primary care physicians, clinics, hospitals, and industrial health care facilities.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, marketing and manufacturing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and plans to invest over $500 million in research and development in 1992.
 -------
 (A) The Compliments of Calcimar program is designed to educate patients about various issues relating to postmenopausal osteoporosis and, at the same time, to help offset the cost of treatment. Patient enrollees who follow their physician's treatment regimen receive free Calcimar, a calcium dietary supplement (Calel-D), and educational materials. Most important, patients also receive a certificate entitling them to a free bone scan. Patients who are interested in the program are encouraged to call the Rhone-Poulenc Rorer toll-free telephone number (800-876-9737) or speak with their doctor about the program.
 ~delval~
 -0- 11~19~92
 ~CONTACT: Bob Pearson of Rhone-Poulenc Rorer, 215-454-3872, or Fran Daniels of CompuMed, 310-278-4413~
 (RPR)


CO: Rhone-Poulenc Rorer Pharmaceuticals; CompuMed, Inc. ST: Pennsylvania IN: MTC SU: JVN

MP -- PH014 -- 2760 11~19~92 10:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1992
Words:482
Previous Article:PHILADELPHIA FED RELEASES NOVEMBER BUSINESS OUTLOOK SURVEY
Next Article:INTERNATIONAL ANNOUNCES DIVIDEND FOR FIRST FISCAL QUARTER
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
RHONE-POULENC RORER AND NOVEN PHARMACEUTICALS SIGN LICENSING AGREEMENT FOR TRANSDERMAL HORMONE REPLACEMENT THERAPY PRODUCTS
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
SMITHKLINE BEECHAM AND DERMIK LABORATORIES SIGN CO-MARKETING AGREEMENT FOR BACTROBAN
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
COMPUMED ACQUIRES RIGHTS TO DETOXAHOL; NEW DRUG TO LOWER BLOOD ALCOHOL CONTENT
RPR Submits Applications for Combination Hormone-Replacement Therapy Patch
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters